Loading...
In Silico Comparison of Bioactive Compounds Characterized from Azadirachta indica with an FDA-Approved Drug against Schistosomal Agents: New Insight into Schistosomiasis Treatment
Oyinloye, Babatunji Emmanuel Shamaki, David Ezekiel Agbebi, Emmanuel Ayodeji Onikanni, Sunday Amos Ubah, Chukwudi Sunday Aruleba, Raphael Taiwo Dao, Tran Nhat Phong Owolabi, Olutunmise Victoria Idowu, Olajumoke Tolulope Mathenjwa-Goqo, Makhosazana Siduduzile
Oyinloye, Babatunji Emmanuel
Shamaki, David Ezekiel
Agbebi, Emmanuel Ayodeji
Onikanni, Sunday Amos
Ubah, Chukwudi Sunday
Aruleba, Raphael Taiwo
Dao, Tran Nhat Phong
Owolabi, Olutunmise Victoria
Idowu, Olajumoke Tolulope
Mathenjwa-Goqo, Makhosazana Siduduzile
Citations
Altmetric:
Genre
Journal article
Date
2024-04-23
Advisor
Committee member
Group
Department
Epidemiology and Biostatistics
Permanent link to this record
Collections
Files
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.3390/molecules29091909
Abstract
The burden of human schistosomiasis, a known but neglected tropical disease in Sub-Saharan Africa, has been worrisome in recent years. It is becoming increasingly difficult to tackle schistosomiasis with praziquantel, a drug known to be effective against all Schistosoma species, due to reports of reduced efficacy and resistance. Therefore, this study seeks to investigate the antischistosomal potential of phytochemicals from Azadirachta indica against proteins that have been implicated as druggable targets for the treatment of schistosomiasis using computational techniques. In this study, sixty-three (63) previously isolated and characterized phytochemicals from A. indica were identified from the literature and retrieved from the PubChem database. In silico screening was conducted to assess the inhibitory potential of these phytochemicals against three receptors (Schistosoma mansoni Thioredoxin glutathione reductase, dihydroorotate dehydrogenase, and Arginase) that may serve as therapeutic targets for schistosomiasis treatment. Molecular docking, ADMET prediction, ligand interaction, MMGBSA, and molecular dynamics simulation of the hit compounds were conducted using the Schrodinger molecular drug discovery suite. The results show that Andrographolide possesses a satisfactory pharmacokinetic profile, does not violate the Lipinski rule of five, binds with favourable affinity with the receptors, and interacts with key amino acids at the active site. Importantly, its interaction with dihydroorotate dehydrogenase, an enzyme responsible for the catalysis of the de novo pyrimidine nucleotide biosynthetic pathway rate-limiting step, shows a glide score and MMGBSA of −10.19 and −45.75 Kcal/mol, respectively. In addition, the MD simulation shows its stability at the active site of the receptor. Overall, this study revealed that Andrographolide from Azadirachta indica could serve as a potential lead compound for the development of an anti-schistosomal drug.
Description
Citation
Oyinloye, B.E.; Shamaki, D.E.; Agbebi, E.A.; Onikanni, S.A.; Ubah, C.S.; Aruleba, R.T.; Dao, T.N.P.; Owolabi, O.V.; Idowu, O.T.; Mathenjwa-Goqo, M.S.; et al. In Silico Comparison of Bioactive Compounds Characterized from Azadirachta indica with an FDA-Approved Drug against Schistosomal Agents: New Insight into Schistosomiasis Treatment. Molecules 2024, 29, 1909. https://doi.org/10.3390/molecules29091909
Citation to related work
MDPI
Has part
Molecules, Vol. 29, Iss. 9
ADA compliance
Embedded videos
License
Attribution CC BY